Cellular immunotherapies such as chimeric antigen receptor therapy are a
promising approach for treatment of multiple myeloma. CAR T-cells have
impressive activity against leukemia and lymphoma, and this has encouraged development of
these therapies for myeloma, James N. Kochenderfer, MD, physician-scientist at Center for
Cancer Research at NCI, said during his presentation.